Charles River Laboratories in the news
Patients Animal Planet People
Tamtam found 20 recent articles about Charles River Laboratories.
- Charles River pays $470M for 2 Frontage bioanalysis labs in Pennsylvania
Charles River Laboratories acquired two Frontage bioanalysis labs in Pennsylvania for $470 million to expand its bioanalysis services and early-stage drug development capabilities.
- HK-listed Frontage to be taken private in $616 million deal backed by Charles River
Frontage Holdings, a Hong Kong-listed company, will be acquired and privatized for $616 million by a consortium backed by Charles River Laboratories.
- Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $324.87, Implies 8% Upside
Charles River Laboratories International Inc. stock's average price target increased to $324.87, suggesting an 8% upside, while maintaining a consensus 'Buy' rating.
- Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch?
Charles River Laboratories International launched Apollo Orchestrate, a digital workflow system for biologics quality control labs, while its stock shows strong recent performance but mixed valuation signals.
- Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories is announcing its third-quarter 2026 earnings release and conference call on November 4th.
- Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories stock increased 1.27% to $301.79, outperforming competitors and the market, and breaking a three-day losing streak.
- Charles River Labs CEO Shannon Parisotto sells $302k in stock
A Charles River Laboratories executive sold over $300,000 worth of company stock after exercising options, amidst a strong performance in the company's share price and analyst optimism.
- Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
Charles River Laboratories International Inc. stock fell 1.53% to $300.30 on Wednesday, marking its second consecutive day of losses amid a broader market downturn.
- Charles River Gains 75.8% in a Year: What's Driving the Rally?
Charles River Laboratories has seen significant stock growth over the past year driven by strong fundamentals, improving RMS prospects, and strategic technological advancements, despite facing uneven demand recovery.
- Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative
Charles River Laboratories International and Autolomous introduced Apollo Orchestrate, a new platform feature designed to digitize GMP quality control workflows across North America and Europe, enhancing efficiency and data traceability.
- Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform
Charles River Laboratories and Autolomous have launched Apollo Orchestrate to digitize laboratory execution and workflow automation for quality control testing within GMP settings.
- Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Charles River Laboratories International's stock price targets and fair value have increased after positive analyst commentary on their long-range plans and margin goals.
- Charles River Laboratories targets $300M in savings through AI tools, automation
Charles River Laboratories is targeting $300 million in savings by investing in AI and automation, particularly in bioanalysis and in vitro testing.
- Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)
Riverwater Partners sold its stake in Charles River Laboratories due to concerns about the impact of FDA regulations on animal testing and to invest in AI stocks.
- Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript
Charles River Laboratories International Inc exceeded Q2 financial targets with improved organic revenue growth, strong DSA segment recovery, and strategic portfolio refinements, despite headwinds in the RMS segment and increased tax rates.
- Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?
Charles River Laboratories provides outsourced research and drug development services for pharmaceutical and biotechnology companies, experiencing increased demand and strong market positioning.
- Charles River CEO shares “the next big transition” in CRO
Charles River Laboratories is enhancing client collaboration and data sharing through a new platform, allowing real-time access to study information and enabling clients to deploy AI for deeper insights.
- NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
Shares of NeoGenomics and Charles River Laboratories fell following a report on accelerating wholesale inflation, impacting the healthcare sector's operating costs and regulatory outlook.
- Charles River Laboratories Introduces AI-Powered, End-to-End Workflow
Charles River Laboratories introduced an AI-powered digital pathology workflow to cut nonclinical study timelines by automating slide quality control and integrating digital tools.
- Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery
ClearBridge Small Cap Growth Strategy recently acquired Charles River Laboratories International, a contract research organization providing drug research services.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Charles River Laboratories?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies